GLP-1 receptor agonists for people with type 2 diabetes and peripheral artery disease: reducing uncertainty in clinical practice
Researchers reviewed the use of GLP-1 receptor agonists in patients with type 2 diabetes and peripheral artery disease. Findings indicate that semaglutide is better than placebo in reducing PAD events, while liraglutide and semaglutide may increase walking distance. Observational studies also show that GLP-1RA use reduces MALE risk. Although dedicated RCTs for hard limb outcomes are lacking, current evidence supports choosing proven effective GLP-1RAs to improve metabolic and walking capacity.
What to check after reading
Current evidence relies on observational studies and subgroup analyses of RCTs, lacking dedicated clinical trials for hard limb outcomes.
Source
Calendar dates show when a case was added or scheduled. For event dates, check the original source.